Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

As of 19 September at 3:42 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), ...

Financial writer bullish on the Health Care Select Sector SPDR ETF (XLV) for its valuation, technical setup, and diversified ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).